open access

Vol 14, No 6 (2019)
Report
Published online: 2019-12-31
Get Citation

Advances in the pharmacological prevention of heart diseases — effective drugs and ineffective diet supplements: evidence from latest AHA and ACC congresses

Dawid Miśkowiec, Jarosław D. Kasprzak
DOI: 10.5603/FC.2019.0117
·
Folia Cardiologica 2019;14(6):648-654.

open access

Vol 14, No 6 (2019)
Report
Published online: 2019-12-31

Abstract

Not available

Abstract

Not available
Get Citation

Keywords

randomized clinical trials, eicosapentaenoic acid, vitamin D3, omega 3 acids

About this article
Title

Advances in the pharmacological prevention of heart diseases — effective drugs and ineffective diet supplements: evidence from latest AHA and ACC congresses

Journal

Folia Cardiologica

Issue

Vol 14, No 6 (2019)

Pages

648-654

Published online

2019-12-31

DOI

10.5603/FC.2019.0117

Bibliographic record

Folia Cardiologica 2019;14(6):648-654.

Keywords

randomized clinical trials
eicosapentaenoic acid
vitamin D3
omega 3 acids

Authors

Dawid Miśkowiec
Jarosław D. Kasprzak

References (10)
  1. Bhatt DL, Steg PG, Miller M, et al. REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019; 380(1): 11–22.
  2. Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis. 2015; 242(1): 357–366.
  3. Mason RP, Dawoud H, Jacob RF, et al. Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin. Biomed Pharmacother. 2018; 103: 1231–1237.
  4. Bhatt DL, Steg PhG, Miller M, et al. REDUCE-IT Investigators. Effects of icosapent ethyl on total ischemic events: from REDUCE-IT. J Am Coll Cardiol. 2019; 73(22): 2791–2802.
  5. Block RC, Liu L, Herrington DM, et al. Predicting risk for incident heartfailure with omega-3 fatty acids: from MESA. JACC Heart Fail. 2019; 7(8): 651–661.
  6. Manson JE, Bassuk SS, Buring JE, et al. VITAL Research Group, VITAL Research Group, VITAL Research Group, VITAL Research Group. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med. 2000; 343(1): 16–22.
  7. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380(4): 347–357.
  8. EMPA-HEART cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes (T2D) and coronary heart disease. http://www.abstractsonline.com/pp8/#!/4682/presentation/59526 (12.04.2019).
  9. Velazquez EJ, Morrow DA, DeVore AD, et al. PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019; 380(6): 539–548.
  10. Intensive vs. standard ambulatory blood pressure lowering to lessen functional decline in the elderly — INFINITY. https://www.acc.org/latest-in-cardiology/clinical-trials/2019/03/16/23/49/infinity (11.08.2019).

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl